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Purpose/Objective: Verification of the calculated and delivered dose 
trough independent verification of treatment planning system (TPS) 
and in vivo dosimetry are important part of the overall radiotherapy 
quality assurance (QA). The verification of TPS was done according to 
IAEA recommendations and put an emphasis on dosimetry part of the 
treatment planning and delivery processes. In vivo dosimetry was 
implemented as quality assurance procedure for patient treatment 
verification. 
Materials and Methods: Verification of TPS was done with 
anthropomorphic phantom which was later also used for in vivo 
measurements prior to patient measurements. Set of clinical test 
cases suggested by the IAEA, covering a range of typical clinical 
radiation techniques found in 3D conformal radiotherapy treatment 
(3D CRT) was used both for TPS and in vivo dosimetry verification. The 
doses were measured with ion chamber and semiconductor diodes, 
and compared to doses calculated in TPS for interest points for test 
cases and points in build up for entrance in vivo readings. 
Consequently, set of breast patients were checked by in vivo during 
their regular treatments. For patient treatment verification, 
tangential half fields were used and in vivo diodes were placed off 
axis, under large gantry angles, with different wedge types and 
angles. 
Results: The measurements were conducted for 6 MV beam energy 
and advanced calculation algorithm. The differences between the 
measured and calculated doses for all test cases were within the 
tolerance level. The differences of in vivo phantom measurements and 
TPS calculation varied depending on the test type: 0.5% for open field 
case to 5.3% for enhanced dynamic wedge (EDW) test case. In vivo 
measurements conducted for breast patients showed difference of not 
more than 5% in comparison with values calculated by TPS.  
Conclusions: After verification of TPS calculation, dose calibration 
and correction factors for semiconductor diodes were checked and 
prediction for in vivo doses in TPS was verified. The errors of 5 % 
magnitude are common in clinics worldwide and clinical 
implementation of in vivo dosimetry in our clinic has given confidence 
that patients are being treated with prescribed dose. This was 
opportunity to systematically review the uncertainties involved in 
treatment planning and dose delivery processes leading to more 
accurate patient treatment. 
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Purpose/Objective: We investigate how QA criteria relate to 
sensitivity end specificity for increased normal tissue toxicity risk and 
risk of decreased tumour control in rotational therapy for prostate 
cancer. 
Materials and Methods: QA analysis for 8 clinical plans and 160 plans 
with deliberately introduced errors was carried out using ten sets of 
QA criteria. The tumour control probability (TCP), and risk of rectal 
bleeding (NTCP_rectum), were calculated. An unacceptable plan was 
defined as a plan where TCP decreased by more than 2%, or the NTCP 
increased by more than 50%, as compared with the clinical plan. We 
chose the 50% NTCP threshold as the rectum was in the low dose 
region. The sensitivity and specificity for detecting unacceptable 
plans and their sum (S+S) were determined for each QA criteria set. 
The diagnostic quality of the QA criteria was also assessed by 
receiver-operator characteristics curves. For dose difference (DD) = 3 
% and distance to agreement (DTA) = 3 mm; the required percentage 
of gamma smaller than 1 for acceptance (A) was scanned and the 
value of A which maximised S+S was determined. In an iterative 
process TCP and TNCP respectively were varied to find the values 
which corresponded to DD=3%, DTA =3 mm and A = 95 %. 
Results: A set of DD = 3 %; DTA = 3 mm and A = 95 % corresponds to 
ensuring that TCP is > 99 %; and NTCP < 160%; of the clinical values. 
For DD = 3 %; DTA = 3 mm, S+S was maximised for A = 95 %. We could 
not identify a single set of QA parameters that was significantly better 
than the others. However, three of the criteria had a significantly 
lower area under the ROC curve than the best parameter sets.  
Conclusions: A method for relating clinical risk estimates to QA 
parameters has been demonstrated. This method can be used to 
determine A for given DD and DTA values once the relative weights of 
sensitivity and specificity have been chosen by the user. It can also be 
used to determine which values of ΔTCP and ΔNTCP correspond to the 
chosen QA criteria set.  
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Purpose/Objective: To assess the accuracy of a three-dimensional 
dose verification technique for patient-specific Quality Assurance (QA) 
in active scanning proton therapy. Critical cases of major deviations 
between treatment planning system (TPS) calculated and measured 
data points are further investigated with Monte Carlo (MC) 
simulations.  
Materials and Methods: Treatment plan verification is performed in a 
water phantom with the simultaneous use of twelve small-volume 
ionization chambers (one data set), aligned in four rows in a way that 
none of them perturbs the other ones. The acceptance threshold is set 
at 5% for both mean deviation between measured and calculated 
doses and one standard deviation, over twelve measurement points. 
Results of 180 data sets, obtained along one year of clinical activity at 
the Italian National Center for Oncological Hadron Therapy (CNAO), 
were analyzed.Data were organized based on tumor site (skull versus 
sacrum) and TPS optimization technique (single field uniform dose 
SFUD versus intensity modulated particle therapy IMPT). A warning 
level was defined for data sets showing more than 30% of single point 
absolute deviations higher than 5% and needing further investigation. 
A MC tool for plan verification in water was implemented to evaluate 
the impact of dose calculation, dose delivery and measurement set-up 
uncertainties on the nine cases resulting out of the warning level.  
Results: All patient-specific quality checks resulted within the 
acceptance threshold. Mean deviation between TPS dose calculation 
and measurement was less than ±3% in 86%of the cases. For targets 
located in the skull region an average higher deviation was found, 
compared to the sacrum region, due to more complex dose patterns 
involved. In addition, the use of a less robust optimization technique, 
such as IMPT compared to SFUD, produced much more scattered 
results and higher single point variation. When all sources of 
uncertainty were accounted for with the MC tool, all the simulated 
cases showed even higher level of agreement, with mean absolute 
deviation ≤ 2% (maximum absolute deviation< 5%). 
Conclusions: Along this first year of clinical activity, the results of all 
patient-specific QA checks performed using ICs in a 3D configuration 
were found within the acceptance threshold. The use of a MC-based 
tool to investigate potential causes of major deviations should be 
further explored, particularly for more complex IMPT plans. 
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Purpose/Objective: This study was performed to examine the effect 
of various factors on the optimization of volumetric modulated arc 
therapy (VMAT) patient specific quality assurance (QA). 
Materials and Methods: Plans were created in eclipse treatment 
planning system (TPS) and measurements were performed in Varian 
Clinac-iX linear accelerator. Fifteen VMAT Plans were compared on 
the basis of type of delivery, number of arcs, complexity (treatment 
site), number of target volumes, and inclusion/exclusion of couch in 
the plans. For the same cases seven field intensity modulated 
radiotherapy (IMRT) plans were also created to compare QA results. 
Planar dose measurements were performed using ImatriXX 2-D array 
system of IBA dosimetry. Percentage of pixels passed the 3%-3 mm 
gamma criterion (% dose difference and distance to agreement-DTA) 
was taken for the comparison. Point dose measurements were also 
performed and the percentage deviation of the calculated doses 
versus measured doses was compared. Student’st-test was performed 
for the statistical analysis of the QA results. 
Results: IMRT plans showed better QA results as compared to double-
arc plans for head & neck site with more than one target volume 
(99.6% vs. 97.91% for the mean percentage of pixels passing the set 
